We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Deltex Medical Group Plc | LSE:DEMG | London | Ordinary Share | GB0059337583 | ORD 0.01P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.12 | 0.11 | 0.13 | 0.12 | 0.12 | 0.12 | 50 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Electromedical Apparatus | 1.78M | -1.28M | -0.0007 | -1.71 | 2.22M |
From May 2019 to May 2024
TIDMDEMG
RNS Number : 1455A
Deltex Medical Group PLC
22 March 2017
Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR).
22 March 2017
Deltex Medical Group plc
("Deltex Medical" or "the Company")
Grant of options
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), today announces that the Board has approved the issue of share options to Ewan Phillips, Chief Executive and Jonathan Shaw, Group Finance Director.
Employee Share Option Scheme
The Board has approved the issue of 658,743 and 404,762 share options to Ewan Phillips and Jonathan Shaw, respectively under the Company's 2003 Share Option Scheme ("EMI"). The exercise price is 1 pence per share option.
The awards were made in return for the directors agreeing to waive gross salary and benefits of GBP17,292 and GBP10,625 respectively.
Confirmation of Directors interest in share options
Following the grant of EMI options above, the options held by the Executive Directors are shown below:
Hot Features
Premium
Executive 2001 Executive 2011 Executive EMI Share
Director Share Scheme Share Scheme Scheme Total
Number Number Number Number
--------------- --------------- --------------- ---------- ----------
Ewan Phillips 1,400,000 2,750,000 2,995,954 7,145,954
Jonathan
Shaw - - 404,762 404,762
--------------- --------------- --------------- ---------- ----------
Additional interests
Following the Subscription announced this morning, Mr Phillips will have a beneficial interest in 2,921,051 ordinary shares in the Company representing 0.98 per cent of the issued ordinary share capital of the Company. Mr Shaw will have a beneficial interest in 262,931 ordinary shares in the Company representing 0.09 per cent of the issued ordinary share capital of the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
The following notifications are made in accordance with Article 19 of the EU Market Abuse Regulation
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Ewan Phillips
--- --------------------------- -----------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Executive Director
--- --------------------------- -----------------------------------
b) Initial notification Initial
/Amendment
--- --------------------------- -----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ----------------------------------------------------------------
a) Name Deltex Medical Group plc
--- --------------------------- -----------------------------------
b) LEI N/A
--- --------------------------- -----------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ----------------------------------------------------------------
a) Description of Unconditional awards over
the financial instrument, Ordinary shares of 1p each
type of instrument in Deltex Medical Group
plc
Identification
code Identification code (ISIN)
for Deltex Medical Group
plc ordinary shares: GB0059337583
--- --------------------------- -----------------------------------
b) Nature of the transaction Share subscription
--- --------------------------- -----------------------------------
c) Price(s) and volume(s) Unconditional award over
658,743 shares under the
Deltex Medical 2003 Share
Option Scheme
--- --------------------------- -----------------------------------
d) Aggregated information
- Aggregated volume
- Price
--- --------------------------- -----------------------------------
e) Date of the transaction 22 March 2017
--- --------------------------- -----------------------------------
f) Place of the transaction Grant of share awards occurred
outside of a trading venue.
--- --------------------------- -----------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Jonathan Shaw
--- --------------------------- -----------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Executive Director
--- --------------------------- -----------------------------------
b) Initial notification Initial
/Amendment
--- --------------------------- -----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ----------------------------------------------------------------
a) Name Deltex Medical Group plc
--- --------------------------- -----------------------------------
b) LEI N/A
--- --------------------------- -----------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ----------------------------------------------------------------
a) Description of Unconditional awards over
the financial instrument, Ordinary shares of 1p each
type of instrument in Deltex Medical Group
plc
Identification
code Identification code (ISIN)
for Deltex Medical Group
plc ordinary shares: GB0059337583
--- --------------------------- -----------------------------------
b) Nature of the transaction Share subscription
--- --------------------------- -----------------------------------
c) Price(s) and volume(s) Unconditional award over
404,762 shares under the
Deltex Medical 2003 Share
Option Scheme
--- --------------------------- -----------------------------------
d) Aggregated information
- Aggregated volume
- Price
--- --------------------------- -----------------------------------
e) Date of the transaction 22 March 2017
--- --------------------------- -----------------------------------
f) Place of the transaction Grant of share awards occurred
outside of a trading venue.
--- --------------------------- -----------------------------------
For further information, please contact:-
Deltex Medical Group 01243 774 837 plc investorinfo@deltexmedical.com Nigel Keen, Chairman Ewan Phillips, Chief Executive Jonathan Shaw, Group Finance Director Nominated Adviser & Broker Arden Partners plc 020 7614 5900 Chris Hardie Financial Public Relations IFC Advisory Ltd 0203 053 8671 Tim Metcalfe Graham Herring Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.
Company goal
ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.
The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.
There are over 3,200 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLFFELVRILFID
(END) Dow Jones Newswires
March 22, 2017 03:15 ET (07:15 GMT)
1 Year Deltex Medical Chart |
1 Month Deltex Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
